Evidence-based Dermatology (2ND)

個数:

Evidence-based Dermatology (2ND)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 723 p.
  • 言語 ENG
  • 商品コード 9781405145183
  • DDC分類 616.5

Full Description


Evidence-based Dermatology, Second Edition is a unique book in the field of clinical dermatology. Written and edited by some of the world's leading experts in evidence-based dermatology, it takes a highly evidence-based approach to the treatment of all major and many of the less common skin conditions. The toolbox at the beginning of the book explaining how to critically appraise different studies, along with the comprehensive reviewing and appraisal of evidence in the clinical chapters makes this book distinctive in its field as do the treatment recommendations which are based on the discussion of the best available evidence using a question-driven approach and a common structure on dealing with efficacy, drawbacks and implications for clinical practice.

Contents

CONTENTS. . Part IHerxheimer, Editor. 1. The field and its boundaries. 2. The rationale for evidence-based dermatology. 3. The role of the consumer and the public in. evidence-based dermatology. 4. The Cochrane Skin Group. Part II: The critical appraisal toolbox. Michael Bigby, Editor. 5. Formulating well-built clinical questions. 6. Finding the best evidence. 7. The hierarchy of evidence. 8. Appraising systematic reviews and meta-analyses. 9. How to critically appraise a randomized controlled trial. 10. How to assess the evidence concerning the safety of medical interventions. 11. What makes a good case series?. 12. What makes a good prevalence survey?. 13. Critical appraisal of pharmacoeconomic studies. 14. Applying the evidence back to the patient. Part III: The evidence. Part IIIa: Common inflammatory skin diseases. Luigi Naldi, Editor. 15. Acne vulgaris. 16. Papulopustular rosacea. 17. Perioral dermatitis. 18. Hand eczema. 19. Atopic eczema. 20. Seborrheic dermatitis. 21. Psoriasis. 22. Lichen planus. 23. Acute urticaria. 24. Chronic urticaria. Part IIIb: Skin cancer, moles, and photoaging. Hywel Williams, Editor. 25. Primary prevention of skin cancer. 26. Do sunscreens reduce the incidence of skin cancers?. 27. Cutaneous melanoma. 28. Squamous cell carcinoma. 29. Basal cell carcinoma. 30. Primary cutaneous T-cell lymphoma. 31. Actinic keratoses and Bowen's disease. 32. Kaposi's sarcoma. 33. Photoaging. 34. Melanocytic nevi. Part IIIc: Infective skin diseases and. exanthema. Hywel Williams and Thomas Diepgen, Editors. 35. Local treatment for cutaneous warts. 36. Impetigo. 37. Athlete's foot. 38. Onychomycosis. 39. Tinea capitis. 40. Deep fungal infections. 41. Streptococcal cellulitis/erysipelas of the lower leg. 42. Exanthematic reactions. 43. Herpes simplex. 44. Leprosy. 45. Cutaneous leishmaniasis. Part IIId: Infestations. Berthold Rzany, Editor. 46. Scabies. 47. Head lice. 48. Insect bites and stings. Part IIIe: Disorders of pigmentation. Berthold Rzany, Editor. 49. Vitiligo. 50. Melasma. Part IIIf: Hair problems. Berthold Rzany, Editor. 51. Male and female androgenetic alopecia. 52. Alopecia areata. 53. Evidence-based treatment of hirsutism. Part IIIg: Leg ulceration. Berthold Rzany, Editor. 54. Venous ulcers. Part IIIh: Other important skin disorders. 55. Cutaneous lupus erythematosus. 56. Dermatomyositis. 57. Acquired subepidermal bullous diseases. 58. Pemphigus. 59. Cutaneous sarcoidosis. 60. Erythema multiforme. 61. Stevens-Johnson syndrome and toxic epidermal necrolysis. 62. Focal hyperhidrosis. 63. Polymorphic light eruption (PLE). 64. Infantile hemangiomas and port-wine stains. 65. Psychocutaneous disease. 66. Pruritus. 67. Other skin diseases for which trials exist. Part IV: The future of evidence-based. dermatology. Luigi Naldi, Editor. 68. Where do we go from here?. Hywel Williams. Additional chapters and resources are published on the book's web site. (www.evidbasedderm.com)

最近チェックした商品